Oligodeoxynucleotide and its use to induce an immune response

US8741869B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US
• Uniformed Services University of the Health Sciences, an institution of higher learning within the Department of Defense · US

Inventors

• Dennis Klinman · Potomac, US
• Ken Ishii · Columbia, US
• Daniela Verthelyi · Potomac, US
• James Mond · Potomac, US

Key dates

• Filing date: Feb 5, 2013
• Grant date: Jun 3, 2014
• Expiry date: Feb 5, 2033

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T428/2989
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula:5′ N1N2N3T-CpG-WN4N5N6 3′wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula:5′ RY-CpG-RY 3′wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.